Innovent’s obesity drug data in adolescents; Everest gets rights to PCSK9 inhibitor
Innovent’s obesity drug data in adolescents; Everest gets rights to PCSK9 inhibitor
Innovent’s obesity drug data in adolescents; Everest gets rights to PCSK9 inhibitor
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.